Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

CoreWeave Shares Tumble Amid Supply Chain Disruption

Felix Baarz by Felix Baarz
November 13, 2025
in AI & Quantum Computing, Earnings, Tech & Software, Trading & Momentum
0
COREWEAVE INC-CL A Stock
0
SHARES
135
VIEWS
Share on FacebookShare on Twitter

The high-flying AI infrastructure provider CoreWeave faces a significant operational challenge. At the very peak of the artificial intelligence boom, the company has jolted investors with an unexpected profit warning and substantial delays in its supply chain. This sudden downturn raises critical questions about the near-term viability of its ambitious growth narrative.

Unwavering Demand Contrasts with Operational Hurdles

Despite these immediate operational difficulties, the underlying demand for AI computing power appears stronger than ever. CoreWeave’s business development team secured an astonishing $25 billion in new orders during the third quarter alone. The company’s total contracted revenue backlog has now swelled to over $55 billion, representing a near doubling from the previous quarter.

Key indicators of this robust demand include:
* Landmark agreements with Meta ($14.2 billion) and OpenAI ($22.4 billion)
* A total of 2.9 gigawatts of contracted capacity
* An additional 1 gigawatt scheduled to come online within the next 12-24 months
* Repeat business from 90% of its top ten enterprise clients

Revised Financial Forecasts Disappoint the Market

In a move that caught the market off guard, CoreWeave has substantially lowered its financial guidance for 2025. The company now projects revenue in the range of $5.05 to $5.15 billion, a reduction from its earlier forecast of $5.15 to $5.35 billion. The primary cause is identified as delivery delays from a key data center partner, issues expected to negatively impact performance throughout the fourth quarter.

Should investors sell immediately? Or is it worth buying COREWEAVE INC-CL A?

The revision to the profit outlook is even more severe. CoreWeave now anticipates its adjusted operating income will land between $690 and $720 million, a sharp drop from the previously guided $800 to $830 million.

Wall Street Reacts with Downgrades and Caution

These developments have prompted a swift reassessment from financial analysts. J.P. Morgan has downgraded its rating on CoreWeave shares from “Overweight” to “Neutral,” simultaneously slashing its price target from $135 to $110. The firm cited escalating supply chain complications now affecting even the leading players in the AI sector. Current technical analysis flags a “very high risk” environment for the stock, driven by extreme price volatility and a consistent pattern of negative trend signals.

Aggressive Capital Expenditure Plans Remain Largely Intact

Showing a long-term commitment to its expansion strategy, CoreWeave is maintaining most of its aggressive capital investment plans, even in the face of current setbacks. The company has budgeted for $12 to $14 billion in capital expenditures for 2025. While this is a reduction from an initial, more ambitious target of $20 to $23 billion, the spending remains substantial. More impressively, the company plans to more than double its investments in 2026, signaling a firm belief in the continued expansion of the AI cloud market.

The central question for investors is whether CoreWeave can swiftly resolve its supply chain bottlenecks and successfully convert its massive order book into realized revenue. The answer will ultimately determine the fate of this former Wall Street darling in the AI space.

Ad

COREWEAVE INC-CL A Stock: Buy or Sell?! New COREWEAVE INC-CL A Analysis from March 25 delivers the answer:

The latest COREWEAVE INC-CL A figures speak for themselves: Urgent action needed for COREWEAVE INC-CL A investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

COREWEAVE INC-CL A: Buy or sell? Read more here...

Tags: COREWEAVE INC-CL A
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026
Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock
AI & Quantum Computing

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
Next Post
Microvast Holdings Stock

Microvast Shares Tumble Despite Record Quarterly Performance

Mastercard Stock

Mastercard Shares Approach Critical Juncture Amid Legal Settlement and Innovation Push

General Electric Stock

GE Shares Continue Their Ascent Amid Diverging Market Views

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com